

Tremelimumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Tremelimumab
ATC codes	L01FX20
Medicine type	Biological agent
EML status history	Application rejected in 2025 (TRS 1064) for Hepatocellular carcinoma of liver Application rejected in 2025 (TRS 1064) for Other specified malignant neoplasms of bronchus or lung
Wikipedia	Tremelimumab ↗
DrugBank	Tremelimumab ↗

Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#)

[Other specified malignant neoplasms of bronchus or lung](#)

